Reported Earlier, Vaxcyte's VAX-31 Demonstrates Robust Immune Responses Across All 31 Serotypes In Lancet-Published Phase 1/2 Adult Study Versus Prevnar 20

Vaxcyte's VAX-31 has shown robust immune responses across all 31 serotypes in a Phase 1/2 study published in The Lancet, leading the company to advance the vaccine into a comprehensive Phase 3 program. The OPUS-1 pivotal noninferiority trial is expected to provide topline data in Q4 2026. VAX-31 demonstrated strong opsonophagocytic activity and a safety profile comparable to Prevnar 20, with the potential to cover approximately 95% of invasive pneumococcal disease in adults aged 50 and older.